TTNP Financials 07/16/2014 08:30:09
Titan Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 10,481 7,117 4,068 10,093
Cost of Revenue - - - -
Gross Profit 10,481 7,117 4,068 10,093
Operating Expenses
Research and Development 8,309 10,610 11,206 12,855
Sales, General and Admin. 3,063 4,877 3,368 3,263
Non-Recurring Items - - - -
Other - - - -
Operating Income (891) (8,370) (10,506) (6,025)
Income From Continuing Operations
Add'l Income/Expense Items 12,170 (1,949) 1,733 (131)
Earnings Before Interest and Tax 11,279 (10,319) (8,773) (6,156)
Interest Expense 1,568 4,861 6,430 678
Earnings Before Tax 9,711 (15,180) (15,203) (6,834)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 9,711 (15,180) (15,203) (6,834)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 9,711 (15,180) (15,203) (6,834)
Preferred Stock and Other Adjustments - - - 1,241
Net Income Applicable to Common Shareholders 9,711 (15,180) (15,203) (5,593)